Tokyo, Japan – Nov. 1, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced the opening of a new subsidiary in the United States in San Jose, California.
“REGiMMUNE is planning to enter clinical studies in the US in 2009, for autoimmune diseases such as GvHD, SLE and MS. To achieve this plan, we have decided to set up our development team on the West Coast of the US. We are determined to expand recruiting activities and also to keep our resources focused on our strategic goal,” commented Mr. Haru MORITA, President and CEO of REGiMMUNE.
Company Name: REGiMMUNE Inc.
Representative: Haru MORITA
Location: 111 N. Market St., 6th Floor, San Jose, CA 95113, USA
Establishment: Nov. 1, 2006
Shareholders: 100% owned by REGiMMUNE Corporation
Business Activities: Development of therapeutic products
REGiMMUNE (www.regimmune.com) is a biotechnology company focused on the immune regulating system for product development using a patented platform technology that can activate the immune regulation system. The technology has been successfully applied to reVax technology, which generated REGiMMUNE’s own pipeline. The company is currently focusing its platform on the development and manufacturing of therapeutic compounds for the treatment of allergies and autoimmune disease.
For Information Contact:
Yuko Amizaki, Director, Corporate Planning
REGiMMUNE.
+81-3-3456-0820